Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease WAYLAND, Mass. – March 10, 2011 – Avaxia Biologics, Inc., a privately-held biotech company using its proprietary pla - Wayland - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-02-06 00:38:22 Malnutrition Wheat Autoimmune diseases Coeliac disease Pediatrics Gluten sensitivity National Institute of Diabetes and Digestive and Kidney Diseases Autoimmunity Biologic Medicine Health Immune system		Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease WAYLAND, Mass. – March 10, 2011 – Avaxia Biologics, Inc., a privately-held biotech company using its proprietary pla Add to Reading List Source URL: www.avaxiabiologics.com Download Document from Source Website File Size: 87,27 KB Share Document on Facebook

	PDF Document DocID: 1xR65 - View Document
	PDF Document DocID: 1xL6Q - View Document
	PDF Document DocID: 1xJoH - View Document
	PDF Document DocID: 1xD0A - View Document
	PDF Document DocID: 1xuZi - View Document